AnaptysBio, Inc. Awarded U.S. Government Contract to Develop Anti-Ricin Antibodies
5/17/2013 8:52:05 AM
More...
|
AnaptysBio, Inc. Develops Novel Antibody Scaffold With Extreme Thermostability
12/4/2012 9:42:31 AM
More...
|
AnaptysBio, Inc. Expands Patent Portfolio with Issuance of U.S. Patent to in Vitro Somatic Hypermutation
10/18/2012 10:49:52 AM
More...
|
AnaptysBio, Inc. Expands Leadership Team With Addition of Dr. Andrew J. Mcknight
8/8/2012 10:34:46 AM
More...
|
AnaptysBio, Inc. Announces Antibody Discovery Partnership With Gilead Sciences, Inc. (GILD)
5/1/2012 11:53:28 AM
More...
|
AnaptysBio, Inc. Announces Strategic Antibody Discovery Partnership With Celgene Corporation (CELG)
4/9/2012 9:08:49 AM
More...
|
AnaptysBio, Inc. Adds Dr. David L. Lacey and Dr. Michael Gallatin to Therapeutic Advisory Board
3/16/2012 9:09:42 AM
More...
|
AnaptysBio, Inc. Announces New Strategic Antibody Discovery
1/9/2012 9:54:08 AM
More...
|
AnaptysBio, Inc. Describes Technology for the Discovery and Optimization of Fully Human Antibodies in Original Research Publication
12/6/2011 9:12:36 AM
More...
|
AnaptysBio, Inc. Appoints Carol G. Gallagher as Executive Chair and Promotes Senior Leaders Hamza Suria and David J. King
10/11/2011 9:21:34 AM
More...
|
|